Palifermin, administered for three doses only, reduces mucositis in patients undergoing HSCT and receiving chemoradiotherapy conditioning

John Coutsouvelis, Michael Dooley, Carl M. Kirkpatrick, Sharon Avery, Ria Hopkins, Andrew Spencer

Research output: Contribution to journalLetterOtherpeer-review


Oral mucositis, a common complication of chemotherapy and/or radiotherapy, presents with varying severity of erythematous and ulcerative lesions. Myeloablative chemotherapy and radiation-based conditioning with autologous and allogeneic haemopoietic stem cell transplantation (auHSCT, aHSCT) are established treatments for haematological malignancies. In these settings, the incidence of severe oral mucositis, defined as World Health Organization (WHO) grade 3 and 4 (G3/4), is reported at 80–100%, with a significant cost burden to health systems. It is described as a feared and incapacitating complication for patients, resulting in pain and difficulty eating, often requiring parenteral opioid analgesia (POA) and parenteral nutrition (PN).
Original languageEnglish
Pages (from-to)1329-1331
Number of pages3
JournalBone Marrow Transplantation
Issue number8
Publication statusPublished - Aug 2022

Cite this